LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 127 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2021. The put-call ratio across all filers is 0.20 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $18,000 | -14.9% | 15,000 | 0.0% | 0.01% | -16.7% |
| Q2 2023 | $21,150 | -6.9% | 15,000 | 0.0% | 0.01% | -14.3% |
| Q1 2023 | $22,725 | +20.7% | 15,000 | 0.0% | 0.01% | 0.0% |
| Q4 2022 | $18,825 | +10.7% | 15,000 | 0.0% | 0.01% | 0.0% |
| Q3 2022 | $17,000 | -29.2% | 15,000 | 0.0% | 0.01% | -22.2% |
| Q2 2022 | $24,000 | +4.3% | 15,000 | 0.0% | 0.01% | +12.5% |
| Q1 2022 | $23,000 | -39.5% | 15,000 | 0.0% | 0.01% | -38.5% |
| Q4 2021 | $38,000 | 0.0% | 15,000 | 0.0% | 0.01% | 0.0% |
| Q3 2021 | $38,000 | -11.6% | 15,000 | 0.0% | 0.01% | -13.3% |
| Q2 2021 | $43,000 | +22.9% | 15,000 | 0.0% | 0.02% | +7.1% |
| Q1 2021 | $35,000 | +34.6% | 15,000 | 0.0% | 0.01% | +27.3% |
| Q4 2020 | $26,000 | +85.7% | 15,000 | 0.0% | 0.01% | +37.5% |
| Q3 2020 | $14,000 | +7.7% | 15,000 | 0.0% | 0.01% | 0.0% |
| Q2 2020 | $13,000 | +8.3% | 15,000 | 0.0% | 0.01% | +14.3% |
| Q1 2020 | $12,000 | -7.7% | 15,000 | 0.0% | 0.01% | +16.7% |
| Q4 2019 | $13,000 | – | 15,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 34,935,485 | $55,198,000 | 4.16% |
| Raffles Associates | 1,930,536 | $3,050,000 | 3.32% |
| Defender Capital, LLC. | 5,131,935 | $8,108,000 | 3.18% |
| Prescott General Partners LLC | 1,851,851 | $2,926,000 | 0.20% |
| DAFNA Capital Management LLC | 140,000 | $221,000 | 0.06% |
| Laurion Capital Management LP | 2,422,367 | $3,827,000 | 0.06% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $71,000 | 0.05% |
| Fort Sheridan Advisors LLC | 78,931 | $125,000 | 0.04% |
| Long Focus Capital Management, LLC | 215,000 | $340,000 | 0.04% |
| MORGAN JESS S & CO INC | 20,000 | $32,000 | 0.03% |